Evidence map›Paper›PMID 38253759›Full record

ArticleMedical oncology (Northwood, London, England)2024

Chitosan-loaded piperlongumine nanoparticles and kaempferol enhance the anti-cancer action of doxorubicin in targeting of Ehrlich solid adenocarcinoma: in vivo and in silico modeling study.

Fawziya A R Ibrahim, Neveen A Hussein, Aisha Y M Soliman, Thanaa I Shalaby, Mona M Rashad, Noura A Matar, Tarek S El-Sewedy

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.9field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Fawziya A R IbrahimDepartment of Applied Medical Chemistry, Medical Research Institute, Alexandria University, 165 El-Horreya Avenue, El-Hadara, Alexandria, Egypt.
Neveen A HusseinDepartment of Applied Medical Chemistry, Medical Research Institute, Alexandria University, 165 El-Horreya Avenue, El-Hadara, Alexandria, Egypt.
Aisha Y M SolimanFaculty of Applied Medical Sciences, Pharos University, Alexandria, Egypt.
Thanaa I ShalabyDepartment of Medical Biophysics, Medical Research Institute, Alexandria University, Alexandria, Egypt.
Mona M RashadDepartment of Applied Medical Chemistry, Medical Research Institute, Alexandria University, 165 El-Horreya Avenue, El-Hadara, Alexandria, Egypt.
Noura A MatarDepartment of Histochemistry and Cell Biology Medical Research Institute, Alexandria University, Alexandria, Egypt.
Tarek S El-SewedyDepartment of Applied Medical Chemistry, Medical Research Institute, Alexandria University, 165 El-Horreya Avenue, El-Hadara, Alexandria, Egypt. tarek.elsewedy@alexu.edu.eg.ORCID http://orcid.org/0000-0003-2937-0657
Alexandria University · EGPharos University in Alexandria · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Doxorubicin is a chemotherapeutic drug that generates free radical-induced toxicities. Natural agents are used to potentiate or ameliorate the toxicity of chemotherapy. None of the studies investigating whether antioxidants or prooxidants should be used with chemotherapy have addressed their efficacy in the same study. Therefore, the aim of this study was to investigate the potential synergy between doxorubicin and two natural rarely in vivo studied anticancer agents; the antioxidant "Kaempferol" and prooxidant "Piperlongumine" in Ehrlich tumor mice model. 77 albino mice were divided into 11 groups; Ehrlich ascites carcinoma cells were injected intramuscularly to develop solid tumors. After 14 days, intratumoral injections of single or combinations of free or Chitosan nanoparticles loaded with doxorubicin, Piperlongumine, and Kaempferol were performed. Tumor Characterization of nanoparticles was measured, tumors were histopathologically examined and evaluation of expression for cancer-related genes by real-time PCR. In silico molecular docking was performed to uncover potential novel targets for Piperlongumine and Kaempferol. Despite receiving half of the overall dose compared to the free drugs, the combined doxorubicin/ piperlongumine-chitosan nanoparticles treatment was the most efficient in reducing tumor volume; down-regulating Cyclin D1, and BCL2; as well as the Beclin-1, and Cyclophilin A genes modulating growth, apoptosis, autophagy, and metastasis, respectively; up-regulating the Glutathione peroxidase expression as a defense mechanism protecting from oxidative damage. When combined with doxorubicin, Kaempferol and Piperlongumine were effective against Ehrlich solid tumors. However, the combination with the Piperlongumine-loaded chitosan nanoparticles significantly enhanced its anticancer effect compared to the Kaempferol or the same free compounds.

Indexed as

AdenocarcinomaBenzodioxolesChitosanAnimalsAntioxidantsComputer SimulationDoxorubicinKaempferolsMiceMolecular Docking SimulationAntioxidantsBenzodioxolesChitosanDoxorubicinKaempferolspiperlonguminineChitosan nanoparticlesDoxorubicinIn silicoKaempferolPiperlongumine

Identifiers

PMID38253759
PMCPMC10803394
OpenAlexW4391116203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.